Prognostic Stage IIA Breast Cancer AJCC v8 Active Not Recruiting Phase 2 Trials for Rifaximin (DB01220)

Also known as: Prognostic Stage 2A Breast Cancer AJCC v8

IndicationStatusPhase
DBCOND0109633 (Prognostic Stage IIA Breast Cancer AJCC v8)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04249622Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast CancerTreatment